US EditionZenara Pharma Receives U.S. FDA Approval for First Generic of Sertraline Hydrochloride Capsules with 180-Day CGT Exclusivity
- Zenara Pharma Private Limited received final approval from the U.S. Food and Drug Administration for its Abbreviated New Drug Application for Sertraline Hydrochloride Capsules, 150 mg and 200 mg.
- This approval marks the first FDA-approved generic equivalent of the reference listed drug marketed by Almatica Pharma, LLC.
- Zenara's ANDA has secured 180 days of marketing exclusivity in the U.S., which commenced with the product's launch.
- Sertraline Hydrochloride Capsules are indicated for the treatment of Major Depressive Disorder and Obsessive-Compulsive Disorder in adults and pediatric patients aged six years and older.
Insights by Ground AI
Does this summary seem wrong?
69 Articles
69 Articles
Johnson City Press+68 Reposted by 68 other sources
Zenara Pharma Receives U.S. FDA Approval for First Generic of Sertraline Hydrochloride Capsules with 180-Day CGT Exclusivity
HYDERABAD, India, July 31, 2025 /PRNewswire/ -- Zenara Pharma Private Limited ("Zenara"), a Biophore company, today announced that it has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Sertraline…
Coverage Details
Total News Sources69
Leaning Left6Leaning Right5Center23Last UpdatedBias Distribution68% Center
Bias Distribution
- 68% of the sources are Center
68% Center
L 18%
C 68%
15%
Factuality
To view factuality data please Upgrade to Premium
